Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Clinical trial NCT05842317 · UNKNOWN
Trial details
- NCT number
- NCT05842317
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2024-04-15
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.